title: TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma.
abstract: BACKGROUND
  Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is a suppressor of TNF-α mediated apoptosis, and its expression is induced by NF-κB activation. TNFAIP8 expression is significantly increased in various cancer cell lines. A correlation between TNFAIP8 overexpression, cancer progression, and poor prognosis has been described in many reports of human solid cancers.
  
  
  METHODS
  To clarify the functional and clinical significance of the cancer progression-related gene, TNFAIP8, in esophageal squamous cell carcinoma (ESCC), we used immunohistochemistry to demonstrate TNFAIP8 expression in ESCC. Next, TNFAIP8 expression was depleted by using siRNA to examine the function of TNFAIP8 in the proliferation and apoptosis induction of ESCC cell lines.
  
  
  RESULTS
  We detected correlations between TNFAIP8 expression and TNM stage (P < 0.001), tumor depth (P = 0.002), lymph node metastasis (P = 0.013), distant metastasis (P = 0.001), lymphatic invasion (P < 0.001), and venous invasion (P < 0.001) among the clinicopathological characteristics of ESCC patients, and high TNFAIP8 expression was found in poor survival. TNFAIP8 depletion was significantly associated with apoptosis induction after cisplatin administration and reduced proliferation.
  
  
  CONCLUSIONS
  Our results suggest that TNFAIP8 might be an effective therapeutic target for ESCC in the future.
authors.affiliation: Department of General Surgical Science (Surgery 1), Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan. yuni_elsa_imoet@yahoo.com
authors.forename: Yuni Elsa
authors.initials: YE
authors.lastname: Hadisaputri
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Shigemasa
authors.initials: S
authors.lastname: Suzuki
authors.forename: Takehiko
authors.initials: T
authors.lastname: Yokobori
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Naritaka
authors.initials: N
authors.lastname: Tanaka
authors.forename: Takanori
authors.initials: T
authors.lastname: Inose
authors.forename: Makoto
authors.initials: M
authors.lastname: Sohda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuwano
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000556:secondary; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D034622:RNA Interference; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C404190:TNFAIP8 protein, human; D002945:Cisplatin